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Effects of Pioglitazone On the Lipid Profile,  
Serum Antioxidant Capacity, and UCP1 Gene 
Expression in Mouse Brown Adipose Tissue 
    





Background: Pioglitazone increases insulin sensitivity and improves glycemic control in type 2 diabetics. In 
this study, we evaluated the effects of pioglitazone on the uncoupling protein 1 (UCP1) expression in mouse 
brown adipose tissue (BAT), and on recovery from oxidative stress due to a high-fat diet. 
Methods: 30 mice were divided into three groups: group 1 received a normal diet, group 2 received a high-fat 
diet, and group 3 received a high-fat diet plus 30 mgkg pioglitazone. After treatment, the cholesterol, 
triglyceride, paraoxonase 1 (PON1), total serum antioxidant capacity (TAC), malondialdehyde (MDA), and 
specific activity of hepatic catalase were measured. BAT UCP1 expression was evaluated at both the mRNA 
and protein levels.  
Results: The weights differed between the groups (p<0.05). Serum MDA was greater and TAC, liver catalase, 
and PON1 were less than in group 2 than in group 1 (p<0.05). In Serum MDA was less and catalase activity 
was greater in group 3 than in group 2 (p<0.05). UCP1 gene expression was less in group 2 than in group 1 
(p<0.05) but greater than in group 3 (p<0.05). 
Conclusions: Pioglitazone may have a protective role in high-fat-diet-induced oxidative stress by increasing 
the antioxidant capacity. Moreover, it can induce weight loss by increasing UCP1 mRNA and protein 
expression.  
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Introduction 
Obesity is a chronic and multifactorial disease 
affected by various psychological, behavioral, 
cellular, molecular, and metabolic factors (1). 
Obesity is characterized by the accumulation of fat 
in body tissues (2), and on a global scale, is 
considered our biggest health problem. Studies 
show that the prevalence of obesity is increasing in 
developing countries, especially in women (3). 
Obesity is one of the most important risk factors for 
developing cardiovascular and chronic kidney 
diseases, as well as diabetes and cancer (4, 5). 
Cardiac fibrosis, causing metabolic disorders such as  
 
 
heart failure and arrhythmia, is also linked to obesity 
(6, 7). In obesity, white adipose cells bulge due to 
the accumulation of triglycerides. In this case, fatty 
acids are released into the bloodstream and insulin 
sensitivity decreases, leading to diabetes. 
Peroxisome proliferator-activated receptors 
(PPARs) act by stimulating adipogenesis, 
regulating fat metabolism in adipocytes, and 
increasing the differentiation of brown adipose 
tissue (BAT) cells. Pioglitazone, a derivative of 
thiazolidinedione, affects lipid metabolism via 
PPARα activation. Activation of PPARs types 1 
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and 2 increases insulin sensitivity and controls 
blood sugar in type 2 diabetics. Because of these 
interactions, free fatty acids reduce types 1 and 4 
glucose transporters and stimulate glucose 
consumption in peripheral tissues, leading to 
induction of insulin signaling pathways and a 
decrease in insulin resistance (8-9). Humans have 
both brown and white adipose tissues; the BAT 
contains polyhedral fat cells with abundant 
mitochondria; unoupling protein 1(UCP1) is 
highly expressed in the mitochondria and plays an 
important role in the thermogenic activity of fatty 
tissue (8). UCP1 decreases the proton gradient by 
transferring protons across the membrane into the 
mitochondrial matrix; in this state, the energy 
from aerobic oxidation produces heat instead of 
ATP. This process controls energy homeostasis 
and keeps living creatures alive at cold 
temperatures. The BAT, as the body’s natural 
anti-obesity organ, burns fat, produces heat, and 
causes weight loss via UCP1 gene expression, 
without affecting the appetite (9, 10). For this 
reason, BAT is widely used in current diabetes 
and obesity-related research (9). Pioglitazone is 
routinely used as an anti-diabetic drug. Therefore, 
the aim of this study was to evaluate the effects of 
pioglitazone on the lipid profile, serum 
antioxidant capacity, and UCP1 gene expression 
in mouse BAT. 
 
Materials and methods 
In this study, 30 six-week-old mice (C-57) with 
an average weight of 20–25 grams were used and 
kept in constant light (12 hours) and temperature 
(22±2 ºC) conditions. The study protocols were 
approved by the Shahrekord University of 
Medical Science Ethics Committee 
(IR.SKUMS.REC.1395.193). 
Mice were randomly separated into three 
groups of 10 mice each. Mice in group 1 received 
a regular diet, mice in group 2 received a high-fat 
diet, and mice in group 3 received a high-fat diet 
plus 30 mgkg body weight of pioglitazone by 
oral gavage. All the mice also received one 
milliliter of distilled water per day by oral gavage. 
The study duration was 30 days. The 
pioglitazone was dissolved in one milliliter of 
distilled water, and all mice in group 3 received 
the pioglitazone by oral gavage in addition to 
high-fat diet daily. The high-fat diet consisted of 
57 percent regular mouse food with 43 percent 
high-fat food, including 15 percent saturated 
animal fat, 5 percent vegetable oil, 20 percent 
sucrose, 2.5 percent cholesterol, and 0.5 percent 
cholic acid.  
After 30 days, the mice were anesthetized with 
chloroform. Blood was collected by heart 
puncture and liver tissue was collected to measure 
hepatic catalase activity. The BAT was excised 
from between the shoulder blades at the back of 
the neck to evaluate UCP1 mRNA and protein 
expression. Tissue samples were washed with 
physiologic serum and stored at -70 °C until use. 
Paraoxonase 1, malondialdehyde (MDA), and 
the lipid profile were measured. The serum lipid 
profile was measured using commercial kits (Pars 
Azmun Company) and an AutoAnalyzer (BT3000, 
Italia). The serum VLDL-C and LDL-C levels 
were calculated using the Friedewald formula. The 
serum antioxidant capacity was measured by 
evaluating its ability to reduce iron (III) to iron (II) 
using the FRAP method (11). The MDA 
concentration was determined by HPLC according 
to the Agarwal method (12). Paraoxonase 1 
activity was measured on a spectrophotometer 
using phenylacetate as the substrate (13). Catalase 
activity was measured via the Abei method (14). 
To measure UCP1 gene expression, total RNA 
was extracted from the BAT using a commercial 
kit (Kit BIOFLUX Trizol Reagent). The RNA 
quality and concentration were determined on a 
Nanodrop (Thermo Scientific Nanodrop 2000 
spectrophotometer, USA). cDNA was synthesized 
using the First Strand cDNA synthesis Kit 
(Thermo Fisher Scientific, USA) according to the 
manufacturer’s guidelines. The primers were 
designed using Oligo 7 software. UCP1 gene 
expression was determined relative to -actin 
expression. The -Actin primers were: (Forward: 
5’-CGGTCAGGTCATCACTATCGG-3’, Reverse: 
5’-TCTTTACGGATGTCAACTCACAC-3’); and 
the UCP1 primers were: (Forward: 5’-
TCAGGATTGGCCTCTACGACT-3’, Reverse: 
5’-GCATTCTGACCTTCACGACCT-3’). The 
UCP1 and -actin genes were amplified on a 
Rotor-gene 3000 (Corbett- Australia).The 
reaction mix was first incubated for 10 min at 95 
°C, then the RT-PCR program consisted of 40 
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cycles of 15 sec at 95 °C, 20 sec at 62 °C, and 20 
sec at 72 °C. UCP1 protein was isolated from the 
BAT using RIPA buffer and its concentration 
was determined using the Bradford method; 
afterward, 40 µg of each sample were 
electrophoresed by SDS-PAGE and transferred 
onto a polyvinylidene difluoride (PVDF) 
membranes. The membrane was blocked with 
bovine serum albumin, and subsequently 
incubated with primary specific antibodies (anti-
beta-actin [ab8227] or anti-UCP1[ab23841]). 
The membrane was washed and then incubated 
with the secondary antibody (anti-rabbit IgG). 
After further washes, one milliliter of enhanced 
chemiluminescence (ECL) solution was added and 
the membrane was scanned. Data were analyzed 
using SPSS version 20 software. The means of the 
groups were compared with one-way ANOVA 
and the groups were compared using the Mann-
Whitney test. In this study, p < 0.05 was considered 
statistically significant. 
Results 
At the end of the study, the group 2 mice were 
significantly heavier than those in groups 1 and 3. 
Group 1 was also significantly heavier than group 
3 (p < 0.05, Fig. 1). The weight differences began 














































Fig. 1. Weekly weight chart. Ten mice were in each group. Group 1 received a normal diet, group 2 received a high-fat diet, and group 3 
received a high fat diet plus 30 mg/kg pioglitazone. Mice were weighed weekly. 
 
After 30 days the serum levels of TG, total 
cholesterol (TC), and LDL-C were greater 
(p=0.004) and HDL-C was less (p=0.03) in 
group 2 than in group 1. Total cholesterol and 
LDL-C were significantly less in group 3 than in 
group 2 (p=0.001). Serum VLDL was 
significantly greater in group 2 than in group 1 
(p<0.05). Serum MDA was significantly greater 
in group 2 than in group 1 (p=0.001) and 
significantly less in group 3 than in group 2 
(p=0.02); also, the serum TAC was significantly 
less in group 2 than in group 1 (p=0.003). Serum 
paraoxonase 1 and liver catalase activities were 
significantly less in group 2 than in group 1 
(p=0.01). Hepatic catalase activity was 
significantly less in group 3 than in group 2 
(p=0.003). Serum glucose in group 2 was 
significantly greater in group 2 than in groups 1 
(p=0.02) and 3 (p=0.001) (Table 1). 
Our data show that the level of the relative 
expression of UCP-1 mRNA, compared to -Actin 
was significantly decreased in group 2, compared to 
the group 1 (p=0.01); while it was significantly 
increased in the third group, compared to the second 
group (p=0.001) (Fig. 2A). 
Also, UCP1 protein was significantly more 
abundant in groups 1 and 3 than in group 2, and 
most abundant in group 3 (Fig. 2B). 
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Values are reported as means ± SEs. each group contained 10 mice. Mice in group 1 received normal diets, those in group 2 received 
high-fat diets, and those in group 3 received high-fat diets plus 30mg/kg pioglitazone. UCP1: Un-coupling protein 1, MDA: 
malondialdehyde, TAC: total antioxidant capacity, HDL-C: high-density lipoprotein, LDL-C: low-density lipoprotein, P<0.05 a is 
considered significantly different from group 1. P<0.05 b is considered significantly different from group 2.  
 
Fig. 2. A) Relative expression of UCP-1 mRNA. Each group contained 10 mice. Mice in group 1 received normal diets, those in group 
2 received high-fat diets, and those in group 3 received high-fat diets plus 30 mg/kg pioglitazone. Mice were fed for 30 days. B) Protein 
level of UCP1/ β-actin. Proteins were extracted from brown adipose tissue, electrophoresed by SDS-PAGE, transferred to PVDF 
membranes, and immunoblotted with anti-UCP or anti-β-actin antibody (upper panel). The differences in blot intensities are reported as 
fold-change (lower panel). 
 
Discussion 
Obesity causes an increase in free radical 
production, leading to an increase in oxidative 
stress. In obesity, a reduction in total antioxidant 
capacity and the activity of enzymes such as 
catalase, contribute to other obesity-related 
problems (1,4,5). Pioglitazone activates PPAR 
types 1 and 2 and improves insulin sensitivity and 
 
glycemic control in type 2 diabetics (8-9). In a 
study by Bahramikia and colleagues. 
LDL-C, TC, and TG were greater, and HDL-C 
less, in rats fed high-fat diets than in controls (15). 
In our study, LDL-C, TC, and TG were 
significantly greater and HDL-C was significantly 
less in group 2 than in group 1. Asdaq et al. 
Group 3 Group 2 Group 1 Variables 
183.7 ± 2.8 185.4 ± 5.1 a 146.8 ± 6.3 Triglyceride(mg/dl) 
212.8 ± 13.2 b 330.4 ± 22.7 a 107.7 ± 2.3 Cholesterol (mg/dl) 
62.25 ± 1.1 61.6 ± 1.6 a 71.7 ± 1.1 HDL-C (mg/dl) 
104.8 ± 14.4 b 208.7 ± 21.4 a 6.7 ± 1.8 LDL-C (mg/dl) 
36.75 ± 0.7 37.0 ± 1.0 a 29.4 ± 1.3 VLDL-C (mg/dl) 
38.6 ± 1.2 b 70.7 ± 2.4a 25.1 ± 1.4 MDA (μM) 
381.2 ± 15.9 360.9 ± 29.2 a 556.0 ± 27.1 TAC (μM) 
37.15 ± 1.21 b 21.1 ± 1.2 a 35.72 ± 2.7 Liver Catalase (unit/mg protein) 
28.9 ± 1.6 23.13 ± 0.8 a 46.3 ± 2.7 Paraoxonase1 (Unit/ml) 
62.2 ± 3.7 b 153 ± 6.8 a 107.7 ± 2.5 Glucose (mg/dl) 
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evaluated the effects of saffron on rats fed high-fat 
diets and reported that the specific activity of 
catalase and the serum total antioxidant capacity 
was less in those rats than in controls (p<0.05) 
(16). Yekta et al. also found that pioglitazone 
activates and increases liver catalase activity (17). 
In our study, catalase activity was greater in group 
3 than in group 2 (p<0.05). Noeman et al. 
reported that MDA was greater and PON1 less in 
rats fed high-fat diets than in controls (18). In our 
study serum PON1 was also less in group 2 than 
in group 1. These changes suggest that in the 
high-fat group, lipids and fatty acids have 
increased and the liver tends to produce more 
triglyceride, resulting in a reduction in HDL 
synthesis. Further, HDL is necessary for PON1 to 
migrate from the liver to the bloodstream, 
whereas a decrease in HDL secretion is 
concomitant with a decrease in serum PON1. 
Serum MDA was greater in group 2 than in group 
1 likely due to the increase in fatty acids and 
decrease in serum antioxidant capacity. Singh et 
al. reported that 30 mg/kg pioglitazone reduced 
serum MDA levels (19). In our study, serum 
MDA in group 3 was less than in group 1. 
Hussian et al. reported that serum glucose, LDL, 
and cholesterol were less in non-diabetic 
hyperlipidemia rats than in controls (20). We 
found that serum glucose, LDL, and serum 
cholesterol levels were significantly less in group 
3 than in group 2. The UCP1 protein expression 
differences seen in our study may be due to the 
high fat consumption in these groups. 
Weight gain and decrease in TAC, catalase 
activity, and serum antioxidant capacity in group 
2 may be due to the high calorie regimen and the 
free radicals produced by the high-fat diet.
    The BAT has an important role in weight and 
metabolism regulation and converts the stored 
energy of TG to heat, via UCP1. Lee et al. 
reported that UCP1 gene expression increased in 
rats fed high-fat diets (21). Shen et al. reported 
that in mice, cinnamon intake decreased blood 
glucose and displayed anti-diabetic effects by 
increasing UCP1 gene expression in BAT and by 
increasing GLUT-4 in muscle and BATs (22). 
Rossato et al. reported that UCP1 gene expression 
in white adipose tissue was induced by the 
activation of cold receptors, subsequently 
increasing heat production (23). Lisa et al. 
reported that pioglitazone increased UCP1 
mRNA and protein expression in the BAT of 
obese diabetic rats (24). Camirand et al. reported 
that thiazolidinediones increase UCP-2 gene 
expression and energy expenditure via PPAR 
production (25). We found that UCP1 gene and 
protein expression was significantly less in group 
2 than in group 1 (p<0.05), which is in contrast 
with the study of Lee et al.; however, UCP1 
protein production was significantly greater in 
group 3 than in group 2 (p<0.05), consistent with 
previous studies. The lack of weight gain seen in 
group 3 is likely due to the increased UCP1 gene 
expression in this group. This study suggests that 
pioglitazone reduces the high-fat-diet-induced 
oxidative stress by increasing lipid and glucose 
catabolism in the body.  
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